Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 213 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
Patents for C07D 213 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members (63,273)
11/2005
11/30/2005CN1229329C Substituted amino amide salicylate with fungal killing function and its prepared intermediate thereof
11/29/2005US6969768 Preparation of 4-haloalkylnicotinic esters
11/29/2005US6969767 5-(haloalkyloxycarbonyloxy)-6-(5-chloropyridin-2-yl)-7-oxo-5,6-dihydropyrrolo[3,4b]pyrazine; enzymatic process for intermediate's synthesis and transformation to (+)-zopiclone
11/29/2005US6969723 preferably antagonists used in the therapeutic and/or preventive treatment of disfunctions of the heart, kidney, respiratory system, central nervous system
11/29/2005US6969715 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
11/29/2005CA2355493C Therapeutic compositions comprising excess enantiomer
11/29/2005CA2351528C Process for the preparation of a piperazine derivative
11/29/2005CA2306004C Process for preparing an aromatic compound substituted by a tertiary nitrile
11/24/2005WO2005110992A1 Amido compounds and their use as pharmaceuticals
11/24/2005WO2005110989A1 Substituted 1-heteroaryl-4-substituted piperazine and piperidine analogues
11/24/2005WO2005110988A1 Pyridone compounds as inhibitors of bacterial type iii protein secretion systems
11/24/2005WO2005110982A2 Substituted 1-benzyl-4-substituted piperazine analogues
11/24/2005WO2005110981A1 Aminoalcohol derivatives
11/24/2005WO2005110975A1 Substituted cyclohexyl-1,4-diamine derivatives with a chain extension
11/24/2005WO2005110971A1 Heteroaryl substituted cyclohexyl-1,4-diamine derivatives
11/24/2005WO2005110401A1 Pharmaceutical nitrones
11/24/2005WO2005110399A2 Zinc-binding groups for metalloprotein inhibitors
11/24/2005WO2005046604A3 Heteroaryl-hydrazone compounds
11/24/2005US20050261503 Heteroaromatic glucokinase activators
11/24/2005US20050261502 2-Amino-4-(1,3-benzodioxol-5-yl)-6-benzyloxy-3,5-pyridinedicarbonitrile, acting as adenosine-receptor-selective ligands, for the prophylaxis and/or treatment of cardiovascular disorders
11/24/2005US20050261499 Process for preparing (r)-aryloxypropionic acid ester derivatives
11/24/2005US20050261497 Catalytic asymmetric hetero diels-alder reaction of a heteroaromatic C-nitroso dienophile: a novel method for synthesis of chiral non-racemic amino alcohols
11/24/2005US20050261371 Administering valproic acid or salts to treat Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, stroke, and other nervous system disorders
11/24/2005US20050261346 N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide;modified amidine elements of high potency in vitro, excellent pharmacological and pharmaceutical properties in vivo
11/24/2005US20050261343 Anthranilamides and their use as pharmaceutical agents
11/24/2005US20050261334 Bis-pyridino containing compounds for the use in the treatment of CNS pathologies
11/24/2005US20050261313 For angiogenesis mediated diseases; cancer; acylation, cyclization and Heck-type reduction
11/24/2005US20050261305 Cyclic protein tyrosine kinase inhibitors
11/24/2005US20050261303 e.g. (2R,5S)-4-(3-chloro-4-cyanophenyl)-N-(2-cyclopropylpyrimidin-5-yl)-2,5-dimethylpiperazine-1-carboxamide; antiandrogenic agent
11/24/2005US20050261293 Compounds which inhibit leukocyte adhesion mediated by VLA-4
11/24/2005US20050261292 Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions
11/24/2005US20050261291 1-Cyclopropylmethyl-4-[2-(3,3,5,5-tetramethylcyclohexyl)phenyl]piperazine or a salt or hydrate; exhibit excellent cell adhesion inhibitory action or cell infiltration inhibitory action; for treating inflammatory diseases and autoimmune diseases such as inflammatory bowel diseases and rheumatoid arthritis
11/24/2005US20050261287 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
11/24/2005US20050261273 Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
11/24/2005US20050260597 Transfection reagents
11/24/2005US20050260126 Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
11/24/2005US20050258400 Nematic or cholesteric or chiral-smectic; high absolute values of dielectric anisotropy combined with a favorable ratio of viscosity to clearing point; light- and UV-stable, and also thermally stable; high voltage holding ratio
11/24/2005DE102004022728A1 Fluorierte Phenanthrene und ihre Verwendung in Flüssigkristallmischungen Fluorinated phenanthrenes and their use in liquid crystal mixtures
11/24/2005CA2566212A1 Heteroaryl-substituted cyclohexyl-1,4-diamine derivatives
11/24/2005CA2565238A1 Amido compounds and their use as pharmaceuticals
11/23/2005EP1598879A2 Luminescence device, display apparatus and metal coordination compound
11/23/2005EP1598361A1 Organic metal complex, electroluminescent material using the complex and ectroluminescent element using the complex
11/23/2005EP1598067A1 Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
11/23/2005EP1597322A2 Metal complexes as light-absorbing compounds in the information layer of optical data carriers
11/23/2005EP1597252A1 Pyridine derivatives as fungicidal compounds
11/23/2005EP1597248A2 Sulfonamide derivatives as ppar modulators
11/23/2005EP1597244A1 Ethynyl derivatives serving as factor xa inhibitors
11/23/2005EP1597232A1 Novel crystalline modification of the anhydrate of boscalid
11/23/2005EP1597223A2 Hydroxyl compounds and compositions for cholesterol management and related uses
11/23/2005EP1377550B9 Phenyl heterocyclyl ether derivatives as serotonin re-uptake inhibitors
11/23/2005EP1372645B1 Reconstitutable parenteral composition containing a cox-2 inhibitor
11/23/2005EP1335898B1 Carbamic acid compounds comprising an amide linkage as hdac inhibitors
11/23/2005EP1320522B1 Compositions and methods of the use thereof achiral analogues of cc-1065 and the duocarmycins
11/23/2005EP1066261B1 Pyridine derivative and pharmaceutical containing the same
11/23/2005CN1701068A Novel compounds and their use
11/23/2005CN1701062A Novel process for the preparation of roflumilast
11/23/2005CN1701061A New compounds for the inhibition of rotamases and use thereof
11/23/2005CN1701059A Chemotherapeutic agents
11/23/2005CN1228337C Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands
11/23/2005CN1228327C Carboxylic acid derivatives and drugs containing the same
11/22/2005US6967253 Method for synthesis of 5-(3-pyridylmethylene-)imidazolidine-2,4-dione
11/22/2005US6967220 antibiotics; treating respiratory system disorders; n-hydroxy benzyl formamide derivatives
11/22/2005US6967208 Anticoagulants; cardiovascular disorders
11/22/2005US6967199 Substituted diamine derivatives useful as motilin antagonists
11/22/2005CA2187174C .alpha.-substituted phenylacetic acid derivative, process for producing the same, and agricultural bactericide containing the same
11/22/2005CA2162122C Use of glycine-n,n-diacetic acid derivatives as biodegradable complexing agents for alkaline earth and heavy metal ions, and method of preparing them
11/22/2005CA2068066C Herpesvirus particles and vaccine
11/17/2005WO2005108384A1 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands
11/17/2005WO2005108381A1 Synthesis and uses of synephrine derivatives
11/17/2005WO2005108380A2 Process employing controlled crystallization in forming crystals of a pharmaceutical
11/17/2005WO2005108370A1 Benzene compounds
11/17/2005WO2005108369A1 Phenyl compounds and their use in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
11/17/2005WO2005108368A1 Adamantyl-acetamide derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
11/17/2005WO2005108367A1 Compounds for treatment of neurodegenerative diseases
11/17/2005WO2005108349A2 Process for preparing atazanavir bisulfate and novel forms
11/17/2005WO2005107762A2 Certain chemical entities, compositions, and methods
11/17/2005WO2005085177A3 Biaryl amino acids and their use in dna binding oligomers
11/17/2005WO2005051906A3 Heterocyclic inhibitors of mek and methods of use thereof
11/17/2005WO2005023204A3 Aromatic prodrugs of propofol, compositions and uses thereof
11/17/2005WO2005016264A3 Diamine derivatives of quinone and uses thereof
11/17/2005US20050256333 4-(3-(2,6-Dimethoxybenzyloxy)phenyl)-4-oxobutyric acid or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis
11/17/2005US20050256314 Process employing controlled crystallization in forming crystals of a pharmaceutical
11/17/2005US20050256202 reacting a solution of atazanavir in acetone solvent with a concentrated sulfuric acid; need to add the seeds of Form A crystals of atazanavir bisulfate to the reaction mixture; salt formation; Form A crystals; HIV protease inhibitor
11/17/2005US20050256201 Phenethanolamine derivatives
11/17/2005US20050256172 1-(3-Pyridyl-2-(N-(2-(3,4-dichlorophenyl)ethyl-N-propylamino)ethanol and a dihydrobromide salt; ligands of sigma receptors; sterol Delta 7,8-isomerase inhibitors; anticholesterol agents; antilipemic agents; hypercholesterolemia and hyperlipemia; side effect reduction due to more targeted action
11/17/2005US20050256170 EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); e.g. (4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl)-acetic acid or 5-Phenyl-furan-2-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide; dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders
11/17/2005US20050256161 Melanin concentrating hormone receptor antagonists
11/17/2005US20050256160 Beta-alanine derivatives and the use thereof
11/17/2005US20050256137 Pyridone compounds as inhibitors of bacterial type III protien secreation systems
11/17/2005US20050256132 Use of ER selective NF-kB inhibitors for the treatment of sepsis
11/17/2005US20050256126 for treatment of microbial infections; potent inhibitors of (bMAP) bacterial aminopeptidase
11/17/2005US20050256123 Heterocyclic inhibitors of MEK and methods of use thereof
11/17/2005US20050256121 Substituted 2,5-heterocyclic derivatives
11/17/2005US20050256116 Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof
11/17/2005US20050256088 condensates of an N-hydroxylamine and pyridoxal, pyridoxal phosphate, and heme-A, or a pharmaceutical salt thereof, and an excipient; prodrugs for releasing hydroxyamines for treating reverse age-related oxidative changes, delay senescence, and reverse mitochondrial decay; neuroprotective agents
11/17/2005US20050256031 Composition for relieving discomfort
11/17/2005US20050255575 Reacting a vinyl halide and an acetylene compound in the presence of a copper (1) bidentate ligand complex, e.g., Cu(1,10-phenanthrolene)(triphenylphosphine)2NO3 and a CuI/neocuproine reaction product; free of expensive palladium reagents
11/17/2005US20050255465 Novel fluorescent label compounds
11/17/2005DE102004018953A1 4-Halogenalkylpyridin-3-sulfonsäureamide, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel 4-haloalkylpyridine-3-sulfonamides, process for their preparation, compositions containing them and their use as pesticides
11/17/2005CA2777216A1 Process for preparing atazanavir bisulfate and novel forms
1 ... 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 ... 633